152 results on '"Madamet, Marylin"'
Search Results
2. Comparison of SD Bioline Malaria Ag Pf/Pan and Acro Malaria P.f./P.v./Pan with Microscopy and Real Time PCR for the Diagnosis of Human Plasmodium Species.
3. Late clinical failure associated with cytochrome b codon 268 mutation during treatment of falciparum malaria with atovaquone–proguanil in traveller returning from Congo
4. Low polymorphisms in pfact, pfugt and pfcarl genes in African Plasmodium falciparum isolates and absence of association with susceptibility to common anti-malarial drugs
5. Are k13 and plasmepsin II genes, involved in Plasmodium falciparum resistance to artemisinin derivatives and piperaquine in Southeast Asia, reliable to monitor resistance surveillance in Africa?
6. Has doxycycline, in combination with anti-malarial drugs, a role to play in intermittent preventive treatment of Plasmodium falciparum malaria infection in pregnant women in Africa?
7. Copper (I)-Chloroquine Complexes: Interactions with DNA and Ferriprotoporphyrin, Inhibition of β-Hematin Formation and Relation to Antimalarial Activity
8. Comparative Assessment of the Sensitivity of Ten Commercial Rapid Diagnostic Test Kits for the Detection of Plasmodium
9. The D113N mutation in the RING E3 ubiquitin protein ligase gene is not associated with ex vivo susceptibility to common anti-malarial drugs in African Plasmodium falciparum isolates
10. Plasmodium falciparum in vitro resistance to monodesethylamodiaquine, Dakar, Senegal, 2014
11. Copper (I)-Chloroquine Complexes: Interactions with DNA and Ferriprotoporphyrin, Inhibition of β-Hematin Formation and Relation to Antimalarial Activity
12. Assessment of a Commercial Real-Time PCR Assay (Vitassay qPCR Malaria 5 Test) to Detect Human Malaria Infection in Travelers Returning to France.
13. Prevalence of Mutations in the pfcoronin Gene and Association with Ex Vivo Susceptibility to Common Quinoline Drugs against Plasmodium falciparum
14. Absence of Association between Methylene Blue Reduced Susceptibility and Polymorphisms in 12 Genes Involved in Antimalarial Drug Resistance in African Plasmodium falciparum
15. Baseline and multinormal distribution of ex vivo susceptibilities of Plasmodium falciparum to methylene blue in Africa, 2013–18
16. Absence of a High Level of Duplication of the Plasmepsin II Gene in Africa
17. Prevalence of Plasmodium falciparum antimalarial drug resistance genes in Southeastern Gabon from 2011 to 2014
18. Baseline Ex Vivo and Molecular Responses of Plasmodium falciparum Isolates to Piperaquine before Implementation of Dihydroartemisinin-Piperaquine in Senegal
19. Global response of Plasmodium falciparum to hyperoxia: a combined transcriptomic and proteomic approach
20. The D113N mutation in the RING E3 ubiquitin protein ligase gene is not associated with ex vivo susceptibility to common anti-malarial drugs in African Plasmodium falciparum isolates
21. Prevalence of Plasmodium falciparum antimalarial drug resistance genes in Southeastern Gabon from 2011 to 2014
22. PROVEBLUE, METHYLENE BLUE, AS AN ANTIMALARIAL DRUG
23. ABSENCE OF ASSOCIATION BETWEEN EX VIVO SUSCEPTIBILITY TO PIPERAQUINE AND POLYMORPHISMS IN EXONUCLEASE GENE AND COPY NUMBERS IN PLASMEPSIN 2 GENE IN AFRICAN PLASMODIUM FALCIPARUM ISOLATES
24. Prevalence of mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, and association with ex vivo susceptibility to common anti-malarial drugs against African Plasmodium falciparum isolates.
25. Plasmodium falciparum Recrudescence Two Years after Treatment of an Uncomplicated Infection without Return to an Area Where Malaria Is Endemic
26. Malaria prophylaxis failure with doxycycline, central African republic, 2014
27. The Plasmodium falciparum chloroquine resistance transporter is associated with the ex vivo P. falciparum African parasite response to pyronaridine
28. The end of a dogma: the safety of doxycycline use in young children for malaria treatment
29. Confirmation of Plasmodium falciparum in vitro resistance to monodesethylamodiaquine and chloroquine in Dakar, Senegal, in 2015
30. Association between Polymorphisms in the Pf mdr6 Gene and Ex Vivo Susceptibility to Quinine in Plasmodium falciparum Parasites from Dakar, Senegal
31. Antibiotics in malaria therapy: which antibiotics except tetracyclines and macrolides may be used against malaria?
32. Failure of dihydroartemisinin plus piperaquine treatment of falciparum malaria by under-dosing in an overweight patient
33. Absence of Association between Polymorphisms in the RING E3 Ubiquitin Protein Ligase Gene and Ex Vivo Susceptibility to Conventional Antimalarial Drugs in Plasmodium falciparum Isolates from Dakar, Senegal
34. Prevalence of anti-malarial resistance genes in Dakar, Senegal from 2013 to 2014
35. Plasmodium falciparumIn Vitro Resistance to Monodesethylamodiaquine, Dakar, Senegal, 2014
36. Delayed Onset of Plasmodium falciparum Malaria after Doxycycline Prophylaxis in a Soldier Returning from the Central African Republic
37. Macrolides and associated antibiotics based on similar mechanism of action like lincosamides in malaria
38. Emergence of Mutations in the K13 Propeller Gene of Plasmodium falciparum Isolates from Dakar, Senegal, in 2013-2014
39. K13-Propeller Polymorphisms in Plasmodium falciparum Isolates from Patients in Mayotte in 2013 and 2014
40. Tetracyclines in malaria
41. Prevalence of <em>Plasmodium falciparum</em> antimalarial drug resistance genes in Southeastern Gabon from 2011 to 2014.
42. Limited polymorphisms in k13 gene in Plasmodium falciparum isolates from Dakar, Senegal in 2012–2013
43. Failure of dihydroartemisinin plus piperaquine treatment of falciparum malaria by under-dosing in an overweight patient.
44. Global response of Plasmodium falciparum to hyperoxia: a combined transcriptomic and proteomic approach
45. Atorvastatin Is a Promising Partner for Antimalarial Drugs in Treatment of Plasmodium falciparum Malaria
46. Atorvastatin Is 10-Fold More Active In Vitro than Other Statins against Plasmodium falciparum
47. Polymorphism in Plasmodium falciparum Drug Transporter Proteins and Reversal of In Vitro Chloroquine Resistance by a 9,10-Dihydroethanoanthracene Derivative
48. Dihydroethanoanthracene Derivatives as In Vitro Malarial Chloroquine Resistance Reversal Agents
49. Absence of Association between Polymorphisms in the RING E3 Ubiquitin Protein Ligase Gene and Ex VivoSusceptibility to Conventional Antimalarial Drugs in Plasmodium falciparumIsolates from Dakar, Senegal
50. Emergence of Mutations in the K13 Propeller Gene of Plasmodium falciparumIsolates from Dakar, Senegal, in 2013-2014
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.